InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,188.80
(
-0.14%
)
Dow Jones
39,127.80
(
0.00%
)
Brent Oil
84.86
(
0.46%
)
Bitcoin
61,159.91
(
0.57%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: DonShimoda post# 17500

Thursday, 03/22/2012 12:46:42 PM

Thursday, March 22, 2012 12:46:42 PM

Post# of 80490
They have some trials going on with MK-2206 (Akt) that will probably do well. Akt is somewhere along the PI3K

http://clinicaltrials.gov/ct2/show/NCT01295632

I think going forward these will probably bear some fruit - but - not before Ariad probably has a lot more data on '113 so all this will be relatively meaningless in the scope of things.

I never really liked ridaforolimus. The combo trials will be were it shows its true efficacy.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up